MeiraGTx Holdings (MGTX) Current Deferred Revenue (2019 - 2025)
MeiraGTx Holdings posted quarterly Current Deferred Revenue of $1.8 million for Q4 2025, down 63.21% year-on-year from $4.8 million in Q4 2024, and down 35.23% on a QoQ basis from $2.7 million in Q3 2025.
MeiraGTx Holdings (MGTX) has 7 years of Current Deferred Revenue data on file, last reported at $1.8 million in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue fell 63.21% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (down 63.21% YoY), and the FY2025 full-year result was $1.8 million, down 63.21% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $1.8 million, down from $2.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $25.6 million in Q1 2021 and bottomed at $1.8 million in Q4 2025.
- The 5-year median for Current Deferred Revenue is $10.0 million (2023), against an average of $11.8 million.
- The widest annual swing landed in 2023, when Current Deferred Revenue tumbled 80.65%; it then jumped 64.97% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $21.8 million in 2021, then sank by 30.69% to $15.1 million in 2022, then sank by 80.65% to $2.9 million in 2023, then surged by 64.97% to $4.8 million in 2024, then sank by 63.21% to $1.8 million in 2025.
- The last three Current Deferred Revenue figures came in at $1.8 million (Q4 2025), $2.7 million (Q3 2025), and $2.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | MeiraGTx Holdings | 856.58 Mn | 790.65 Mn | 74.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.78 Mn |
| Sep 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Mar 31, 2025 | 4.24 Mn |
| Dec 31, 2024 | 4.83 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 3.77 Mn |
| Dec 31, 2023 | 2.93 Mn |
| Sep 30, 2023 | 7.92 Mn |
| Jun 30, 2023 | 12.06 Mn |
| Mar 31, 2023 | 13.69 Mn |
| Dec 31, 2022 | 15.12 Mn |
| Sep 30, 2022 | 18.88 Mn |
| Jun 30, 2022 | 21.21 Mn |
| Mar 31, 2022 | 20.19 Mn |
| Dec 31, 2021 | 21.82 Mn |
| Sep 30, 2021 | 23.00 Mn |
| Jun 30, 2021 | 24.88 Mn |
| Mar 31, 2021 | 25.60 Mn |
| Dec 31, 2020 | 23.55 Mn |
| Sep 30, 2020 | 23.72 Mn |
| Jun 30, 2020 | 23.00 Mn |
| Mar 31, 2020 | 20.93 Mn |
| Dec 31, 2019 | 25.68 Mn |
| Sep 30, 2019 | 24.12 Mn |
| Jun 30, 2019 | 26.32 Mn |
| Mar 31, 2019 | 20.95 Mn |